Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialReetta Virtakoivu, Maija Hollmén|Clinical Cancer Research|2021Cited by 53
Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacyStuart Prince, Maija Hollmén|Theranostics|2025Cited by 8